Press Release Details
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
Kiniksa intends to use the net proceeds from the offering to advance the development of its product candidates, to advance commercialization activities and to fund other research and development activities as well as for working capital and general corporate purposes.
Kiniksa has filed a registration statement (including a prospectus) with the
A preliminary prospectus supplement related to the offering (including the accompanying prospectus) will be filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s clinical stage product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These pipeline assets are designed to modulate immunological signaling pathways that are implicated across a spectrum of diseases.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the completion, timing and size of the proposed offering, expectations with respect to granting the underwriters a 30-day option to purchase additional Class A common shares, and our intended use of any net proceeds from the proposed offering.
These forward-looking statements are based on management’s current plans, estimates or expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, risks and uncertainties related to global economic or market conditions, volatility in the share price of our Class A common shares, changes in our operating plan or funding requirements and satisfaction of customary closing conditions.
These and other important factors discussed under the caption “Risk Factors” in our Form 10-Q for the three months ended
Every Second Counts!™
Kiniksa Investor and Media Contact
Source: Kiniksa Pharmaceuticals, Ltd.